Cohen & SteersNYSE: CNS

Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. As part of the event, Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discussed the unmet need in glioblastoma multiforme (GBM), the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.

HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been granted an exception until March 11, 2025, to regain compliance with the minimum bid price requirement in Listing Rule 5550(a)(2). About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

SAN FRANCISCO--(BUSINESS WIRE)--Elastic (NYSE: ESTC), the Search AI company, today announced its successful collaboration with LG CNS, a leading digital transformation company in Korea, to help transform the company's global knowledge management services with enhanced search for generative AI (GenAI). LG CNS's KeyLook AI search algorithm is a retrieval augmented generation (RAG) system developed at its in-house AI Center. The company has integrated Elasticsearch into its search algorithm, incre.

NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Cohen & Steers (NYSE: CNS) announced today that funds managed by the Private Real Estate Group of Cohen & Steers and the Investment Management business of Acadia Realty Trust (NYSE: AKR – "Acadia"), a publicly traded owner and operator of retail properties in the U.S., have entered into a joint venture to own The Walk at Highwoods, an open-air community shopping center in Tampa, Florida. The Walk at Highwoods is a 141,000 square foot power center located approximately 20 miles northeast of downtown Tampa in a high-growth suburban area.

New Platform Provides Real-Time Traffic Analytics, Threat Intelligence, Application Layer Protection, and Anti-Bot DDoS Defense To Enhance Service Availability and Security MARLBOROUGH, Mass. , Oct. 29, 2024 /PRNewswire/ --  Corero Network Security  (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, announces the launch of its new cloud-based availability protection platform, CORE.

HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 17,647,060 shares of common stock (or common stock equivalents in lieu thereof) pursuant to a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $0.17 per share. The closing of the offering is expected to occur on or about October 24, 2024, subject to the satisfaction of customary closing conditions.

Cohen & Steers' Q3 2024 results exceeded expectations, with revenue up 9.4% YoY and non-GAAP adjusted EPS up 13.5% YoY. Significant AUM growth and a return to positive net inflows drove the strong financial performance for Cohen & Steers in the recent quarter. CNS' near-term prospects are favorable, with expected revenue and earnings growth due to increased investor real estate allocations and the company's private real estate AUM expansion.

Cohen & Steers, Inc. (NYSE:CNS ) Q3 2024 Earnings Conference Call October 17, 2024 10:00 AM ET Company Participants Brian Heller - Senior Vice President and Corporate Counsel Jon Cheigh - Chief Investment Officer Joseph Harvey - Chief Executive Officer and President Raja Dakkuri - Chief Financial Officer Conference Call Participants John Dunn - Evercore ISI Benjamin Rubin - UBS Operator Ladies and gentlemen, thank you for standing by. Welcome to the Cohen & Steers Third Quarter 2024 Earnings Conference Call.

NEW YORK , Oct. 16, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended September 30, 2024. The earnings release along with the accompanying earnings presentation can be viewed at Cohen & Steers Reports Results for Third Quarter 2024 and on the company's website at www.cohenandsteers.com under "Company—Investor Relations—Earnings Archive.